Morgan Stanley Sees Growth Platforms Building for Stericycle

In a report published Thursday, Morgan Stanley analyst David R. Lewis reiterated an Equal-Weight rating on Stericycle SRCL. In the report, Morgan Stanley noted, “Organic revenue growth in 4Q13 ticked up slightly versus 3Q13 but remains consistent with 2012-13 trends. Greater traction from StrongPak is a modest positive but drove margin dilution. Full valuation and limited visibility on sustainable growth acceleration keeps us from a more constructive view.” Stericycle closed on Wednesday at $116.48.